|
|
- 2019
T Cell-Redirecting Strategies to ‘STAb’ Tumors: Beyond CARs and Bispecific AntibodiesDOI: https://doi.org/10.1016/j.it.2019.01.008 Abstract: Current FDA-approved strategies geared towards redirecting T cell activation against tumor cells include the expression of chimeric antigen receptors (CARs) by T cells, and the passive administration of bispecific antibodies (bsAbs) targeting CD3 and a TAA
|
